BlossomHill Therapeutics (NASDAQ:BLSM) Stock Price Down 5.6% – What’s Next?

Shares of BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) traded down 5.6% during mid-day trading on Monday . The company traded as low as $18.31 and last traded at $18.46. 36,449 shares changed hands during trading, a decline of 84% from the average session volume of 227,586 shares. The stock had previously closed at $19.56.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of BlossomHill Therapeutics to a “hold” rating in a report on Saturday, August 15th.

BlossomHill Therapeutics Trading Down 6.5%

Insiders Place Their Bets

In other BlossomHill Therapeutics news, General Counsel Vincent Paul Liptak bought 2,200 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $35,200.00. Following the completion of the purchase, the general counsel directly owned 111,412 shares in the company, valued at $1,782,592. The trade was a 2.01% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Carl L. Gordon purchased 625,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the transaction, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This represents a 29.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 1,573,900 shares of company stock valued at $25,181,900 over the last 90 days.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.